A total of 4 pts were discontinued prior to expected end of treatment (1 depression, 1 pneumonia, 1 unrelated trauma, and 1 who could not be reached for follow up). Adverse events were limited to anemia and rash (none serious), and were appropriately managed by the primary providers. CONCLUSIONS: Carfilzomib The Synchronous Cohort approach to teleconferencing with primary care providers offered multiple advantages (1) Simultaneous treatment milestones and adverse event management, enhancing

the learning experience for which the ECHO model is known to be effective (2) Coordination of laboratory results (3) Focused work-ups and patient education based on synchronous treatment initiation (4) Less intrusive impact on the busy primary care focused clinics (5) Treatment outcomes as good as or better than those reported from specialty practices Variable Univariate Analysis Multivariable Analysis   Odds Ratio [95% CI] p-value Odds Ratio

[95% CHIR-99021 research buy CI] p-value HCC 2.97 [1.27–6.95] 0.01 3.64 [1.42–9.35] 0.007 Diuretic 3.57[2.13–6.0O] < 0.001 2.27 [1.23–4.17] 0.008 MELDS≧15 3.49 [2.07–5.90] < 0.001 2.22 [1.21–4.07] 0.01 Unmarried 1.90 [1.15–3.15] 0.01 1.92 [1.10–3.35] 0.02 Admission during baseline year 4.09 [2.45–6.82] < 0.001 2.17 [1.21–3.89] 0.01 ICU admission during baseline year 2.04 [0.91–4.54] 0.08     Alcoholic cirrhosis (vs. hepatitis C-related cirrhosis) 2.18 [1.23–3.84] <,0001     ED visit during baseline year 6.66 [2.12–20.90] 0.001     CCI (per one point increase) 1.17 [1.09–1.26] < 0.001     Diabetes mellitus 1.67 [0.98–2.85] 0.06 - - Congestive heart failure 1.90 [0.98–3.70] 0.06 -   Lactulose or rifaximin 2.11 [1.24–3.59] 0.006     SBP prophylaxis 2.58 [1.26–5.27] 0.009     Ascites 7.38 [3.77–14.47] < 0.001   Disclosures: The following people have nothing to disclose: Ann Moore, Richard A. Manch mafosfamide Purpose: Many patients are not eligible for interferon-based therapy due to the presence

of relative or absolute contraindications. The objective of this study was to measure real-world treatment and treatment completion rates in patients with comorbidities. Methods: We evaluated treatment rates in 2010 (pre-protease inhibitors [PIs]) and 2012 (post-PIs) among 2,040 chronic HCV patients with medical and psychosocial comorbidities using a large US commercial and Managed Medicare database. Psychosocial comorbidities included alcohol abuse, bipolar disorder, depression, drug abuse, and schizophrenia. Medical comorbidities included chronic renal disease, heart failure, portal hypertension, and cirrhosis. We evaluated treatment completion rates and stratified by comorbidities and treatment regimens. Results: Treatment rates were low among HCV patients overall (8–12%), but even lower for those with comorbidities (Table 1).